DIABETIC MACULAR EDEMA

This study tests an oral drug called Kamuvudine-9 (K9) in 10 adults with diabetic macular edema, a condition where fluid builds up in the eye and blurs vision. The goal is to see if K9 is safe and if it can improve eyesight better than a placebo. Participants will be randomly ass…

This study tests whether levosulpiride, a drug already used for other conditions, can safely improve vision and reduce retinal swelling in people with diabetic retinopathy and diabetic macular edema. About 120 adults aged 40-69 with mild to moderate eye damage will receive either…

This early-stage trial tests an oral drug called MS-553 in 45 people with diabetic macular edema, a condition where fluid builds up in the eye's center, blurring vision. Participants take the drug daily for 8 weeks to see if it is safe and can reduce swelling or improve eyesight.…

This study tests a new medicine called AVT29 against an existing drug, Eylea HD, for people with diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. About 256 adults will receive either AVT29 or Eylea HD to see if AVT29 works just as well at…

This study tests an eye implant called EYP-1901 that slowly releases medication to treat diabetic macular edema, a condition that causes vision loss in people with diabetes. About 240 adults with this eye condition will receive either the implant or standard aflibercept injection…

This study compares having one laser treatment session versus several sessions for people with proliferative diabetic retinopathy, a serious eye condition that can lead to blindness. Researchers want to see which approach is safer and works better. About 40 adults with diabetes a…

This early-phase study tests an experimental drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition that causes vision loss. About 93 participants will receive the drug alone or with another approved medicine (faricimab) to check safety and…

This phase 3 study tests whether a new drug, EYP-1901, works as well as the standard treatment aflibercept for diabetic macular edema, a condition that causes vision loss. About 240 adults with DME will receive either EYP-1901 or aflibercept injections. The goal is to see if EYP-…

This study tests a small implant placed in the eye that releases medication every 24 weeks to treat diabetic macular edema, a leading cause of vision loss in people with diabetes. About 634 adults with the condition will receive either the implant or standard monthly eye injectio…

This study will follow about 1,000 people in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will track vision changes, eye thickness, and treatment patterns over one year to see ho…

This early-stage study tests a new drug called OCU200 for people with diabetic macular edema, a condition that causes vision loss due to swelling in the retina. The main goal is to check safety, but researchers will also measure vision changes and eye pressure. About 24 adults wi…

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab in real-world clinics. Researchers will track vision changes, treatment schedules, and safety over two years. The goal is …

This study involves 150 people with diabetic macular edema (DME) who are either starting treatment with anti-VEGF injections or a dexamethasone implant, or have not been treated before. Researchers will measure various substances in the blood and use eye scans to see if these mar…